Clinuvel Pharmaceuticals Limited

ASX:CUV ISIN:AU000000CUV3

 Clinuvel Pharmaceuticals Limited (ASX:CUV) is a leading and innovative Australian company focused on the development of afamelanotide, its proprietary first-in-class photoprotective drug. Clinuvel has identified five groups of patients with a clinical need for photoprotection. Currently, Clinuvel is in its final stages to complete testing of afamelanotide in Phase II and III trials in Australia and Europe. 
 

News

Clinuvel Pharmaceuticals Limited (ASX:CUV) Successful Drug Trial Results For Light Intolerant Shadow Jumpers

🕔7/13/2010 10:21:29 AM 6100

Results released today from a Phase III trial of the drug SCENESSE (R), conducted by Melbourne-based Clinuvel Pharmaceuticals Limited (ASX:CUV) (PINK:CLVLY), have shown that the drug has the ability to reduce and prevent painful phototoxic reactions experienced by patients with erythropoietic protoporphyria (EPP).

Read Full Article

Clinuvel Pharmaceuticals Limited (ASX:CUV) Novel UV Protecting Drug Delivered By The Picogram

🕔7/8/2010 10:36:26 AM 6951

Melbourne's Clinuvel Pharmaceuticals Limited (ASX:CUV) (PINK:CLVLY) today signed with a commercial US partner to manufacture its world's first photoprotective drug, SCENESSE (R), under an exclusive arrangement. Following eight years of development, Clinuvel has selected Surmodics, Inc. (NASDAQ:SRDX), a leading Minnesota-based provider of proprietary drug delivery technologies to the healthcare industry, as its first manufacturing partner.

Read Full Article
###

5,590 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 3) (Last 30 Days: 29) (Since Published: 5590) 

Company Data

    Headquarters
  • Level 11, 330 Collins Street
    Melbourne VIC 3000
    Australia
  • Telephone
  • +61-3-9660-4900 
  • Fax
  • +61-3-9660-4999 
  • Principal Sector
  • Health & Pharm General 
  • Principal Industry
  • Healthcare 
  • Homepage
  • www.clinuvel.com

More News Results

  • 2024/07/05: Notification of cessation of securities - CUV*
  • 2024/07/05: Afamelanotide Assists DNA Repair Response Following UVR*
  • 2024/06/28: CLINUVEL extends Managing Director Employment Agreement*
  • 2024/06/28: Change of Company Secretary*
  • 2024/06/24: SCENESSE European Orphan Drug Designation for VP*
  • 2024/06/18: afamelanotide in fair-skinned Parkinsons patients*
  • 2024/06/11: CLINUVEL Newsletter III - June 2024*
  • 2024/06/05: Update - Notification of buy-back - CUV*
  • 2024/06/03: CLINUVEL withdraws label expansion for adolescent EPP*
  • 2024/05/24: Ceasing to be a substantial holder*
*refer to company website